Drugs / 18-PSMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06935149 | Oct 2025 → Apr 2026 | metastasis from malignant tumor of colon | Primo Biotechnology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18-PSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06935149 ↗ |
| Modality | Diagnostic / imaging agent | “diagnostic utility of PSMA PET” NCT06935149 ↗ |
| Route | Intravenous | “Intravenous push” NCT06935149 ↗ |